Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Ion mobility diagnostic test directly measures lipoprotein particles

Quest Diagnostics : 04 June, 2008  (Company News)
Quest Diagnostics has released results of a study that demonstrates that a novel diagnostic testing technique is the first to provide direct, accurate and reproducible physical measurement of both the size and concentration of a broad range of lipoproteins in blood plasma.
'Our data suggest that this novel ion mobility-based method offers advantages over other procedures for lipoprotein particle analysis because it both measures particle size accurately on the basis of physical principles as well as directly counts the particles present at each size independently of particle composition. We believe this approach provides the only direct physical measurement of lipoprotein particle size and concentration for each lipoprotein subclass, from small HDL to large VLDL,' said Richard E Reitz, MD, co-lead investigator and acting vice president, Science and Innovation, and medical director, Quest Diagnostics Nichols Institute. 'We look forward to learning the results of additional research to identify the technique's clinical utility for risk assessment and treatment in patients with cardiovascular disease and related conditions.'

Lipoprotein particles are fatty substances carried through the blood stream that affect cardiovascular health. High-density lipoproteins (HDL), referred to as ‘good’ cholesterol, promote healthy cardiovascular function, but LDL and very-low density lipoproteins (VLDL), or ‘bad’ cholesterol, may deposit on the walls of arteries, promoting atherosclerosis and other cardiovascular diseases. Because particles of LDL, intermediate-density lipoprotein (IDL) and VLDL each contain one apolipoprotein B (ApoB) protein, ApoB concentration may give a better indication of large lipoprotein particle concentration than measurements of cholesterol concentrations alone.

The American Diabetes Association and American College of Cardiology Foundation recently published a consensus statement that recommends physicians use ApoB measurements to guide therapy in individuals with cardiometabolic risk who are on statin therapy. Yet, clinically available methods of measuring lipoprotein particle subpopulations are not standardised and generally use an algorithm to indirectly measure lipoprotein particle concentrations.

The objective of the study, conducted by Quest Diagnostics Nichols Institute, was to describe and validate the ability of the ion mobility technique to directly and accurately measure plasma lipoprotein particles, covering the spectrum of HDL, LDL, IDL and VLDL in healthy adults.

Approximately 260 healthy male and female adults who met the National Cholesterol Education Program's Adult Treatment Panel III guidelines for optimal plasma lipid and lipoprotein concentrations were recruited to establish reference distributions for the lipoprotein fractions detected by the method. Concentrations of total HDL, HDL Large, total LDL, total IDL, total VLDL, and non-HDL particles were determined using the ion mobility technique and correlated with biochemical measurements of calculated triglycerides, HDL cholesterol, LDL cholesterol as well as plasma ApoA1 and ApoB.

Results showed that the ion mobility technique was precise in measuring LDL particle size, producing a variation of less than one percent over approximately 48 preparations of the same sample. The HDL and LDL concentrations varied less than 20 percent in these same preparations. The study also found a strong correlation (r=0.92) between the non-HDL (LDL, IDL and VLDL combined) concentration and the plasma concentration of ApoB, the single protein present in all non-HDL particles.

The strong correlation of ApoB with non-HDL particles using the ion mobility technique was expected, as both provide measurements of lipoprotein concentration. The comparatively poorer correlation with cholesterol reflects the varying concentrations of this compound within lipoprotein particles, underscoring the ion mobility technique's potentially unique advantage over other methods. Specifically, while other techniques generally depend on cholesterol measurements to determine particle concentration, the ion mobility method measures lipoprotein particle concentration and size regardless of the particle's lipid, protein, triglyceride and cholesterol content.

Independent researchers expect this year to complete their review of an outcomes study designed to determine if the technique provides clinically useful information for predicting and monitoring cardiovascular disease in patients.

'While more research and development is required, we are excited by the findings of our analytical research, which clearly demonstrates that our ion mobility technique can measure particle size and concentrations using a direct, rather than algorithm-based method,' said Michael P Caulfield, PhD, scientific director, Research and Development, Endocrinology, Quest Diagnostics Nichols Institute, and one of the study's investigators. 'Depending on the results of the third-party outcomes study, we are optimistic that our ion mobility technique will provide the basis for developing a high- throughput standardised diagnostic test that will enable physicians to more accurately understand the unique lipoprotein characteristics of the individual patient.'

The new technique uses the principles of ion mobility to provide direct measurement of particles. Ion mobility determines particle size based on the drift velocity of ion-charged particles as they pass through a layer of air under the force of an electric field. Ion mobility, which is commonly used to analyze aerosols, is employed in nanotechnology, proteomics and drug development.

In 2004, Quest Diagnostics co-exclusively licensed certain ion mobility patents for lipoprotein analysis from Ernest Orlando Lawrence Berkeley National Laboratory in Berkeley, California, USA, and subsequently utilised the patent rights to develop its own test. Quest Diagnostics now has two patents pending for further technological advances.

In addition to Dr Reitz, Ronald M Krauss, MD, director of Atherosclerosis Research, the Children's Hospital Research Institute (CHORI), Oakland, CA, was a co-lead investigator on the study. Dr Krauss co-developed the original patent while a senior scientist in the Life Sciences Division of Berkeley Lab.

Quest Diagnostics funded the study, which is titled ‘Direct Determination of Lipoprotein Particle Sizes and Concentrations by Ion Mobility Analysis’.
Results of the study were published in the May 29, 2008, online edition of Clinical Chemistry.

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo